Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.

Mol Med Rep · 2016 · PMC5042754 · PMID 27499118

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

A borderline significant relative survival benefit was observed in MET-treated patients compared with non-MET-treated patients [hazard ratio (HR), 0.80; 95% confidence interval (CI), 0.62–1.03] in a pooled analysis of four publications containing 1,429 patients ( 33 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.